Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Horizon Discovery Group Plc

11 Dec 2020 17:32

GFGW LLC - Form 8.3 - Horizon Discovery Group Plc

GFGW LLC - Form 8.3 - Horizon Discovery Group Plc

PR Newswire

London, December 11

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:GF GW, LLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.· Glick Family Gold Mountain Trust & Pluchenik Family Gold Mountain Trust (trustee, settlor and beneficiaries for both trusts are: Pax PT Company LLC, Louis Glick and Issue of Louis Glick, respectively.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeHorizon Discovery Group Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure9/12/2020
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:1p ordinary share
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:2,239,9111.41%
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:2,239,9111.41%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
1p ordinaryPurchase30,217186p
1p ordinaryPurchase647,299186.5p
1p ordinaryPurchase62,395187p

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:December 9, 2020
Contact name:Shmuel Lieberman
Telephone number*:212.259.0375

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
18th Apr 20167:00 amRNSChange of Adviser
7th Apr 20167:00 amRNSNotice of Results
24th Mar 201612:29 pmRNSAdditional Listing
24th Mar 20168:54 amRNSAdditional Listing
15th Mar 20167:00 amRNSHorizon Discovery hosts symposium on gene editing
2nd Mar 20167:00 amRNSHorizon Discovery Group forms Immuno-oncology JV
26th Jan 20164:04 pmRNSHolding(s) in Company
22nd Jan 20161:21 pmRNSHolding(s) in Company
18th Jan 20167:00 amRNSTrading Update
15th Jan 20164:14 pmRNSAdditional Listing
12th Jan 201610:09 amRNSAdditional Listing
17th Dec 20159:52 amRNSDirector/PDMR Shareholding
11th Dec 20159:23 amRNSAdditional Listing
25th Nov 20157:00 amRNSThree diagnostic agreements worth an initial $3.3m
13th Nov 20157:00 amRNSDirector Dealings
12th Nov 20151:30 pmRNSBoard Change
12th Nov 20157:00 amRNSHolding(s) in Company
12th Nov 20157:00 amRNSHolding(s) in Company
6th Nov 20153:51 pmRNSDirector/PDMR Shareholding
29th Oct 20157:00 amRNSTotal Voting Rights
28th Oct 20157:00 amRNSNew E-Commerce Platform and UK Headquarters
21st Oct 20158:48 amRNSAdditional Listing
15th Oct 20155:44 pmRNSGrant of options under Long Term Incentive Plan
7th Oct 20154:00 pmRNSIssue of Equity
7th Oct 20157:00 amRNSIn-licensing agreement with Servier
22nd Sep 20157:00 amRNSHalf Yearly Report
18th Sep 201510:17 amRNSAdditional Listing
16th Sep 20157:00 amRNSCell Line Licensing Agreement with LakePharma Inc
9th Sep 20157:00 amRNSHZD & Abcam plc Sign License & Supply Agreement
3rd Sep 20157:00 amRNSCancer Research Collaboration with Redx Pharma
3rd Sep 20157:00 amRNSCancer Research Collaboration
1st Sep 201511:49 amRNSAdditional Listing
1st Sep 20157:04 amRNSNotice of Interim Results
27th Jul 20157:00 amRNSHZD To Invest c£10M In Cancer R&D
20th Jul 20157:00 amRNSTrading update
17th Jul 201512:34 pmRNSAdditional Listing
19th Jun 201511:28 amRNSResult of AGM
26th May 20154:46 pmRNS2014 Annual Report and Accounts & AGM Notification
22nd May 20153:28 pmRNSHolding(s) in Company
21st May 20156:04 pmRNSHolding(s) in Company
18th May 201511:50 amRNSResult of General Meeting and Issue of Equity
14th May 20157:00 amRNSDirectorate Change
5th May 20157:01 amRNSCorrection to Results of Placing
1st May 20154:15 pmRNSResults of Placing
1st May 201511:08 amRNSProposed placing and Notice of General Meeting
23rd Apr 20157:00 amRNSHORIZON AND TRANSGENOMIC SIGN OEM AGREEMENT
20th Apr 20157:00 amRNSHorizon & Thermo Fisher Scientific Sign Agreement
14th Apr 20157:07 amRNSPreliminary Results
10th Apr 20153:30 pmRNSAdditional Listing
27th Mar 20158:29 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.